Profile data is unavailable for this security.
About the company
Tibet Weixinkang Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of chemical pharmaceutical preparations and their active pharmaceutical ingredient. The Company's main products include multivitamins for injection (12), multi-trace element injection, pediatric multivitamin injection (13), compound electrolyte injection (V), potassium magnesium aspartate injection, potassium aspartate injection and other products. The Company is also engaged in pharmaceutical marketing services. The Company mainly conducts its businesses in the domestic market.
- Revenue in CNY (TTM)1.26bn
- Net income in CNY247.04m
- Incorporated2006
- Employees701.00
- LocationTibet Weixinkang Pharmaceutical Co Ltd3F, Block 4, Industry Center, No. 5Yuanqu South Road, Zone B, Lasa EconomicLASA 850000ChinaCHN
- Phone+86 8 916601760
- Fax+86 8 916601760
- Websitehttp://www.wxkpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Aidea Pharmaceutical Co Ltd | 408.68m | -104.55m | 3.85bn | 476.00 | -- | 3.60 | -- | 9.43 | -0.2384 | -0.2384 | 0.9459 | 2.54 | 0.2193 | 0.9553 | 2.66 | 858,576.30 | -5.65 | -2.40 | -8.32 | -2.85 | 48.96 | 39.00 | -25.77 | -10.15 | 1.11 | -- | 0.3018 | -- | 68.44 | 8.24 | 38.75 | -- | -4.47 | -- |
| Tibet Weixinkang Pharmaceutical Co Ltd | 1.26bn | 247.04m | 4.13bn | 701.00 | 16.72 | 2.79 | -- | 3.29 | 0.5677 | 0.5677 | 2.89 | 3.41 | 0.6778 | 16.41 | 5.56 | 1,791,483.00 | 13.33 | 8.20 | 17.01 | 11.13 | 53.45 | 50.20 | 19.67 | 11.53 | 3.27 | -- | 0.0075 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
| Chengdu Olymvax Biopharmaceuticals Inc | 530.47m | -8.70m | 4.17bn | 471.00 | -- | 4.58 | -- | 7.87 | -0.0219 | -0.0219 | 1.31 | 2.24 | 0.3301 | 0.3685 | 1.04 | 1,126,255.00 | -0.9143 | 3.17 | -1.28 | 4.68 | 94.19 | 93.00 | -2.77 | 7.44 | 1.67 | -0.5392 | 0.2915 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
| Zhejiang Starry Pharmaceutical Co Ltd | 2.37bn | 13.89m | 4.18bn | 1.85k | 189.96 | 1.57 | -- | 1.77 | 0.0502 | 0.0502 | 5.72 | 6.08 | 0.4094 | 1.74 | 6.76 | 1,284,337.00 | 0.2471 | 3.30 | 0.4806 | 5.97 | 21.35 | 32.35 | 0.6036 | 8.21 | 0.4855 | 1.21 | 0.4994 | 53.08 | 3.04 | 19.78 | 158.32 | -13.94 | 10.39 | -- |
| Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 713.75m | 233.79m | 4.26bn | 1.14k | 18.02 | 1.91 | -- | 5.97 | 1.19 | 1.19 | 3.63 | 11.26 | 0.2367 | 0.7194 | 7.25 | 624,455.80 | 7.75 | 10.04 | 9.09 | 11.63 | 80.01 | 83.66 | 32.75 | 28.29 | 3.48 | -- | 0.2098 | 47.86 | -5.39 | 8.93 | -8.39 | 18.78 | 12.23 | 17.13 |
| Lionco Pharmaceutical Group Co Ltd | 277.20m | -101.80m | 4.26bn | 475.00 | -- | 4.98 | -- | 15.38 | -0.144 | -0.144 | 0.3828 | 1.19 | 0.1843 | 2.48 | 4.41 | 583,571.30 | -6.77 | 0.7396 | -7.85 | 0.9562 | 41.77 | 80.88 | -36.73 | 2.08 | 4.94 | -4.74 | 0.2409 | 521.93 | -31.95 | -34.79 | 22.65 | -- | -33.18 | -- |
| Yabao Pharmaceutical Group Co Ltd | 2.83bn | 220.70m | 4.38bn | 4.14k | 19.92 | 1.49 | -- | 1.55 | 0.3057 | 0.3057 | 3.86 | 4.10 | 0.7389 | 3.51 | 6.66 | 683,686.80 | 5.11 | 2.82 | 6.38 | 3.97 | 52.85 | 59.20 | 6.92 | 4.19 | 2.04 | 129.51 | 0.0313 | 43.74 | 7.05 | -0.0572 | 90.71 | -6.10 | 7.98 | -9.71 |
| Pulike Biological Engineering Inc | 1.09bn | 101.68m | 4.39bn | 1.68k | 42.91 | 1.65 | -- | 4.05 | 0.296 | 0.296 | 3.13 | 7.72 | 0.3373 | 2.48 | 2.65 | 646,748.50 | 3.16 | 7.64 | 3.73 | 8.96 | 60.45 | 62.57 | 9.36 | 17.85 | 2.51 | -- | 0.0086 | 52.48 | 1.84 | 15.55 | 3.99 | 5.17 | 41.58 | 18.47 |
| Shanghai New World Co Ltd | 1.13bn | 45.48m | 4.42bn | 1.20k | 97.30 | 1.05 | -- | 3.90 | 0.0703 | 0.0703 | 1.75 | 6.53 | 0.201 | 3.94 | 10.25 | 942,735.10 | 0.7905 | 0.5242 | 1.05 | 0.7249 | 38.77 | 33.70 | 3.93 | 2.71 | 1.57 | -- | 0.1158 | 82.75 | 33.39 | -16.40 | 160.85 | -35.00 | 53.61 | -25.42 |
Data as of Sep 13 2024. Currency figures normalised to Tibet Weixinkang Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Essence Fund Co., Ltd.as of 30 Jun 2024 | 1.48m | 0.34% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 380.70k | 0.09% |
| Xiangcai Fund Management Co. Ltd.as of 30 Jun 2024 | 359.50k | 0.08% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 256.00k | 0.06% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 220.00k | 0.05% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2024 | 199.00k | 0.05% |
| Nanhua Fund Management Co. Ltd.as of 30 Jun 2024 | 188.70k | 0.04% |
| Broad Fund Management Co. Ltd.as of 30 Jun 2024 | 139.60k | 0.03% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 121.50k | 0.03% |
| Western Leadbank Fund Management Co., Ltdas of 30 Jun 2024 | 73.70k | 0.02% |
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
